title: Colorectal Cancer Yields to Dual HER2 Blockade.
abstract: According to data from a phase II study, the anti-HER2 combination of trastuzumab and lapatinib is active in patients with KRAS-wild-type, HER2-positive metastatic colorectal cancer. None of the study participants responded to previous, standard treatment with the EGFR inhibitors cetuximab or panitumumab, but 30% achieved an objective response to dual HER2 blockade.
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics; D018572:Disease-Free Survival; D006801:Humans; D000077341:Lapatinib; D009154:Mutation; D009362:Neoplasm Metastasis; D016283:Proto-Oncogene Proteins p21(ras); D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics; D000068878:Trastuzumab / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000077341:Lapatinib; D016283:Proto-Oncogene Proteins p21(ras); D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C117307:KRAS protein, human; C508053:ERBB2 protein, human